Stock To Buy | Is Amgen A Good

The market is hyper-focused on MariTide , Amgen’s monthly-dose obesity candidate, which could disrupt the current weekly-dose market dominated by Eli Lilly and Novo Nordisk.

In 2025, revenue grew 10% to $36.8 billion , with non-GAAP earnings per share (EPS) rising to $21.84 . is amgen a good stock to buy

Amgen's appeal lies in its ability to generate massive cash flow while aggressively pivoting its portfolio to offset upcoming biosimilar competition. The Bull Case The market is hyper-focused on MariTide , Amgen’s

Recent moves, such as the $840 million deal for Dark Blue Therapeutics, bolster its oncology pipeline in areas like acute myeloid leukemia (AML). The Bear Case The market is hyper-focused on MariTide